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Background: Skeletal muscle dysfunction contributes to exercise limitation in COPD. The
role of the nitric oxide synthase (NOS) system in muscle dysfunction is ill defined. Reduced
levels of endothelial NOS (eNOS) and elevated levels of inducible NOS (iNOS) in the skeletal
muscle of COPD patients have been recently reported. We hypothesized that resistance
exercise training (R) and/or testosterone supplementation (T) would alter the transcription
and expression of the NOS isoenzymes in COPD skeletal muscle.
Methods: Vastus lateralis biopsies were obtained before and after a 10-week intervention in
40 men with severe COPD(age 67.7  8.3, FEV1 41.4  12.6% predicted): placebo þ no
training (P) (n Z 11), placebo þ resistance training (PR) (n Z 8), testosterone þ no training
(T) (n Z 11) and testosterone þ resistance training (TR) (n Z 10) groups. eNOS, nNOS and
iNOS mRNA and protein levels were measured in each sample. mRNA and protein levels
were measured using real-time PCR and enzyme-linked immunosorbant assay, respectively.
Results: eNOS mRNA increased in the TR group compared to P and T groups (P < 0.001).
eNOS protein was increased in TR and T groups after intervention (P < 0.05) but not in
the PR group. nNOS protein increased in the PR, T, and TR groups (P < 0.05). iNOS protein
decreased only in the TR group (P Z 0.01).n Clinical Trials Center, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, 1124
502, USA. Tel.: þ1 310 222 8200; fax: þ1 310 222 8249.
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270 B. Chavoshan et al.Conclusion: Resistance training and testosterone supplementation increased eNOS and nNOS
proteins and decreased iNOS protein in the skeletal muscles of men with COPD. These
changes in NO system might explain some of the favorable effects of these therapies.
ª 2011 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a major
medical burden worldwide and is projected to become the
fifth leading cause of disability by 2020.1,2 Exercise intol-
erance, the main disabling factor and symptom of COPD, is
mediated in part by skeletal muscle dysfunction.3,4 Mech-
anisms involved in skeletal muscle dysfunction in COPD
include decreased capillarity, decreased aerobic enzyme
activity, increased apoptosis, oxidative stress, inflamma-
tion, malnutrition, muscle disuse, ubiquitin-mediated
proteolysis and decreased anabolic hormone levels.5e10
Previous studies have employed therapeutic strategies
such as endurance training, resistance training and anabolic
hormone administration, to overcome skeletal-muscle
dysfunction in COPD patients .11,12 We previously reported
that resistance (strength) training and weekly injection of
testosterone separately and combined together led to
increased leg lean mass and strength in men with COPD.13,14
Analysis of vastus lateralis muscle biopsy specimens
demonstrated these interventions yielded muscle fiber
remodeling, mediated partly through the insulin-like
growth factor-1 (IGF-1) system.14 However, it was not
determined whether these interventions had salutary
effects on the nitric oxide synthase (NOS) system, which
plays a role in inflammatory and oxidative stress processes
in COPD patient’s skeletal muscles.15,16 In the present study
we performed messenger ribonucleic acid (RNA) and
protein assays relevant to the NOS system on these muscle
biopsy specimens.
The NOS system has been suggested as playing a role in
skeletal muscle dysfunction in COPD.16 The constitutive
isoforms, endothelial NOS (eNOS) and neuronal NOS (nNOS),
preserve low vascular tone, prevent endothelial platelet
and leukocyte adhesion, and neuro-regulate local blood
flow. Local NO levels generated by inducible NOS (iNOS)
isoform during inflammatory responses are more than 1000
times higher than amounts generated by eNOS and nNOS.17
High iNOS-stimulated NO concentrations, accompanied by
other inflammatory end-products, may exert the cytotoxic
effects of NO observed in COPD patients.18 Montes-de-Oca
et al. reported decreased eNOS and nNOS levels, as well
as markedly elevated iNOS levels in muscles of severe COPD
patients.16 These high iNOS isoform levels might lead to
toxic amounts of NO and contribute to muscle dysfunction
in COPD as well as in other chronic diseases such as
congestive heart failure.19e22 It has been shown that
exercise training in chronic heart failure patients modifies
the NOS system.23
Thus, we hypothesized that testosterone administra-
tion and resistance training are associated with
decreased skeletal muscle iNOS and increased eNOS and
nNOS. The aim of this study was hence to examine
changes in levels of mRNA and proteins of different NOSisoforms in the vastus lateralis before and after testos-
terone injections and resistance training in COPD men
who participated in a 10-week randomized placebo-
controlled trial.
Methods
Subjects
We originally enrolled 53 men with stable COPD.13 Briefly,
inclusion criteria included age 55e80 years, forced expi-
ratory volume in 1 s (FEV1) of 60% predicted or less,
24 and
FEV1 to vital capacity ratio of 60% or less. Screening serum
testosterone was 400 ng/dl or less (i.e., in the lower range
for healthy older men). Exclusion criteria included signifi-
cant cardiovascular or orthopedic impairments, body mass
of less than 0.75 or more than 1.3 fraction of ideal, symp-
tomatic benign prostatic hypertrophy, history of prostate
cancer, serum prostate specific antigen of more than 4 mg/
L, or hemoglobin of more than 16 g/dl. The institutional
review board had approved the study, and all participants
signed written informed consent.
Study design
Vastus lateralis needle biopsies were obtained before and
after the interventions as part of a parallel but separate
protocol from the main trial. In 40 subjects, tissue was
successfully obtained in both time points. These subjects
had been randomized to: (A) placebo and no resistance
training (P, n Z 11), (B) placebo and resistance training
(PR, nZ 8), (C) testosterone and no resistance training (T,
n Z 11), and (D) testosterone and resistance training (TR,
n Z 10) groups. Randomization of subjects was stratified
based on age (below or above 67 years) and FEV1 (less or
greater than 40% predicted).
Interventions
Testosterone supplementation
Subjects received 100 mg/week of testosterone enanthate
in sesame oil (Delatestryl) or placebo (sesame oil) intra-
muscularly for 10 weeks. This testosterone dose was
intended to raise nadir serum testosterone to the middle of
the normal range for healthy young men (i.e.
450e850 ng dl1). Testosterone levels were measured
immediately before the second injection and an unblinded
investigator (not involved in data analysis) made dosage
alterations.
Resistance training focused on muscles of ambulation
An exercise trainer supervised three sessions per week of
the exercise training. Training consisted of seated leg
Table 1 Primers used for cDNA synthesis and real-time RT-PCR analysis.
Primer Name Primer Sequence (50–30) Product Length (bp) GeneBank Accession Code
iNOS Sense: AGC ATG TAC CCT CGG TTC TG
Antisense: CAG GTG GGA CAG CTT CTG AT
60 U31511
eNOS Sense: ACC CTC ACC GCT ACA ACA TC
Antisense: CTG GCC TTC TGC TCA TTC TC
208 AF400594
nNOS Sense: GGA ATC CAG GTG GAC AGA GA
Antisense: GGG CAG AGG TTT GTG TGA CT
51 D16408
GAPDH (control) Sense: GTC TCC AGA ACA TCA TCC
Antisense: CAC CAC CTT CTT GAT GTC
182 M33197
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raise, and seated ankle dorsiflexion. Subjects performed
three sets of each exercise per session. For the first 4
weeks, the training target was 3 sets of 12 repetitions at 0.6
fraction of the pre-training one-repetition maximum.
Intensity was increased when subjects completed all 36
repetitions of a given exercise. When 3 sets of 12 repeti-
tions were again achieved, loads were increased. After 4
weeks of training, one-repetition maximum values were
reassessed and used for the remaining 6 weeks. Subjects
performed four sets of 8e10 repetitions, using 0.8 fraction
of the new one-repetition maximum for each training
exercise; the intensity was subsequently advanced as
tolerated.Analysis of biopsy specimens
Tissue fluid was blotted from the biopsy specimens, and fat
and connective tissue were rapidly dissected from the
muscle. Biopsy specimens were frozen at 80 C and batch
assayed 1e5 years after the samples were obtained. A
portion of these samples was analyzed by Lewis et al.14 At
the same time, we analyzed the muscle samples indepen-
dently to measure NOS messenger ribonucleic acid (mRNA)
and proteins. The mRNA was assayed by real-timeTable 2 General characteristics and baseline pulmonary functi
Placebo þ No Training
(n Z 11)
Placebo þ Resis
Training (n Z 8
Age, yr 68.6  8.6 68.0  10.8
Height, cm 176.8  5.6 179.8  8.4
Body Mass, kg 82.2  14.4 81.0  22.2
Baseline
testosterone,
ng/dl
302  161 297  92
FEV1, L 1.26  0.44 1.20  0.36
FEV1, %
predicted
38.8  12.4 37.2  10.8
FEV1/VC 42.08  10.6 38.6  7.3
TLC, L 7.63  1.70 7.98  1.42
DLCO,
ml/min/mmHg
13.1  4.2 12.0  6.1
Values are presented as Mean  SD FEV1, forced expiratory volume in
diffusing capacity of the lung for carbon monoxide.polymerase chain reaction (PCR) as previously described14
using published sequences for eNOS, iNOS and nNOS
(Table 1). Total muscle protein concentration was deter-
mined based on the Bradford method (Bio-Rad, Hercules,
CA, USA). Protein levels of eNOS and iNOS were measured
by enzyme-linked immunosorbant assay (ELISA) kits con-
taining antibodies against human eNOS and iNOS, respec-
tively (R&D Systems, Minneapolis, MN, USA). A similar assay
was used to determine nNOS protein using recombinant
human nNOS (Alexis Biochemicals, San Diego, CA, USA) and
antibodies against human nNOS (BD Biosciences, San Diego,
CA, USA). All samples were processed and analyzed in the
same laboratory with the same machinery and by a single
experienced investigator to minimize variability.
Statistical analysis
Analysis of variance (ANOVA) with Tukey post-hoc compar-
ison was employed to examine the differences of contin-
uous variables across the 4 groups. Wilcoxon-signed ranked
test was employed to compare quantities of NOS isoform
proteins before and after intervention in each treatment
group. To examine changes of mRNA and proteins after the
intervention period, we calculated fold changes by dividing
quantity of post-intervention of each measurement by pre-
intervention quantity. SPSS Ver. 12.0 (Chicago, IL, USA) wason findings of the study participants.
tance
)
Testosterone þ No
Training (n Z 11)
Testosterone þ Resistance
Training (n Z 10)
67.6  7.2 67.6  7.4
176.8  5.3 177.3  7.4
85.6  15.2 91.7  24.0
297  116 425  137
1.55  0.68 1.45  0.44
43.7  15.9 44.1  11.0
43.0  14.9 47.1  12.7
8.06  0.79 7.51  1.46
13.6  6.0 13.4  7.7
the 1st second; VC, vital capacity; TLC, total lung capacity; DLCO,
Figure 1 Abundance of mRNA transcripts for nitric oxide
synthase (NOS) isoforms. There were significant fold-change
increases in abundance of eNOS isoform (Upper Panel) in TR
patients compared to P and T groups over the 10-week inter-
vention (P < 0.001). Values are expressed as fold change from
baseline (horizontal line); thus, a value of 1-fold indicates no
change following intervention. P: placebo and no resistance
training (nZ 11), PR: placebo and resistance training (nZ 8),
T: testosterone and no resistance training (n Z 11), and TR:
testosterone and resistance training (n Z 10) ) Significantly
different from P and from T. Values are mean  SEM.
272 B. Chavoshan et al.used for statistical analysis. P values <0.05 were consid-
ered statistical significant.
Results
General characteristics
General characteristics and pulmonary function tests of the
participants in each of the four intervention groups are
presented in Table 2. The four groups were not significantly
different in terms of age, height, body mass or pulmonary
function tests. Further, the 13 randomized subjects who did
not provide paired muscle biopsy specimens had a lower
FEV1 (0.98 vs. 1.38 L, p < 0.009) and higher TLC (9.07
vs.7.79 L, p < 0.003) than the 40 who did, but did not differ
significantly in other characteristics. In the report of the
body composition and strength changes observed in the
larger trial,13 we reported that both resistance-trained and
testosterone groups significantly increased leg lean muscle
mass. Further, the leg lean muscle mass in the combined
testosterone and resistance-training group was significantly
greater than in resistance training alone. The combination
of testosterone and resistance training increased quadri-
ceps strength significantly greater than testosterone alone.
Transcription of nitric oxide isoforms in the vastus
lateralis
Fig. 1 shows the fold changes (end of intervention divided
by baseline value) in the abundance of mRNA of NOS iso-
forms in vastus lateralis muscle according to the treatment
group; a value of one-fold (horizontal line) indicates no
change following the intervention.
Across the intervention groups, significant increment in
eNOS mRNA abundance was observed in the TR patients
compared to the P and T groups (P < 0.001) (upper panel).
However, there was no statistically significant difference in
fold change of nNOS and iNOS mRNA across the 4 groups of
intervention (Fig. 1, middle and lower panels).
Translation of nitric oxide isoforms in the vastus
lateralis
Fig. 2 shows the abundance of the three isoforms of NOS in
the skeletal muscles of COPD men after the 10-week inter-
vention as compared with the pre-intervention value. As
shown in the upper panel of the Fig. 2, the fold-change of
the eNOS protein was statistically significantly greater in the
TR group compared to P group (1.62  0.54 vs. 1.09  0.17,
P Z 0.008). Furthermore, the middle panel of the Fig. 2
shows that the fold changes in nNOS protein in the PR, T
and TR groups were significantly greater than the P group
(P < 0.001). Finally, the lower panel of the Fig. 2 shows that
fold change of the iNOS protein after the 10-week inter-
vention was not different among P, PR, and T groups.
The absolute amounts of NOS proteins before and after the
interventionaredepicted inFig. 3.eNOSprotein (upperpanel)
was significantly increased in the TR and T groups after
intervention (P < 0.05); however, there was no significant
change in the eNOS protein following 10 weeks of resistance
Figure 2 Abundance of eNOS, nNOS and iNOS proteins in
skeletal muscles of men with COPD. The fold-change increment
for eNOS protein was significantly greater in TR compared to
the P group. The fold-change increment for nNOS protein in the
PR, T, and TR groups was significantly greater than the P group.
Values are expressed as fold change from baseline (horizontal
line). P: placebo and no resistance training (n Z 11), PR:
placebo and resistance training (nZ 8), T: testosterone and no
resistance training (n Z 11), and TR: testosterone and resis-
tance training (n Z 10) ) Significantly different from P
(p < 0.05); values are means  SEM.
Figure 3 Concentrations of muscle eNOS, nNOS and iNOS
proteins (upper, middle and lower panels, respectively) before
and after the 10-week intervention. Compared to baseline,
eNOS protein levels were significantly increased in T and TR
groups (upper panel). nNOS protein was also significantly
increased in the PR, T, and TR groups. iNOS protein was
significantly increased only in the TR group. P: placebo and no
resistance training (n Z 11), PR: placebo and resistance
training (n Z 8), T: testosterone and no resistance training
(nZ 11), and TR: testosterone and resistance training (nZ 10)
) Significantly different from baseline (i.e. after vs. before
intervention); values are mean  SEM.
NOS isoforms, testosterone and training in COPD 273training alone (i.e., the PR group). nNOS protein (middle
panel) significantly increased in the PR, T, and TR groups
(P < 0.05). Finally, iNOS protein (lower panel) decreased
following intervention only in the TR group (PZ 0.012).
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In men with severe COPD and low baseline testosterone
levels, eNOS mRNA levels increased in both resistance-
trained groups. In contrast, eNOS protein levels increased
in both testosterone-treated groups. nNOS mRNA levels did
not change significantly in any of the groups whereas nNOS
protein levels increased in all intervention groups. iNOS
mRNA levels also did not change significantly in any group,
while iNOS protein levels decreased significantly only in the
group receiving both testosterone replacement and resis-
tance training.
From multiple studies over the last few decades, it is
clear that the physiologic role of NO depends on the loca-
tion and time course of its release. NO released by the
vascular endothelium is responsible for maintaining a low
vascular tone. NO present in skeletal muscle has a neuro-
modulatory effect. NO released by inflammatory cells is
highly toxic to invading organisms. Thus the same molecule
has multiple (and potentially conflicting) roles based on the
location of its release. The apparent discrepancy between
mRNA and protein levels that we observed might be
explained by several factors. It would be expected that
changes in mRNA and protein levels follow different time
courses with the mRNA levels leading the protein levels. As
the second biopsy was obtained at the end of the ten-week
study period and on a non-exercise day, changes in mRNA
levels present early in the course of intervention might
have been missed.
In contrast to endurance training, little is known about
the effects of resistance training on the levels of NOS iso-
forms in skeletal muscle. In both the human and the rat,
much of the skeletal muscle eNOS is located in the micro-
vasculature.25,26 Endurance training increases the number
of eNOS-containing structures in the muscles of healthy
young humans25 and eNOS protein levels in rats.26 The
effect of resistance training on eNOS levels has not been
conclusively established.27 In our study, we observed
increases in eNOS levels in the testosterone-treated groups.
It is of relevance that castration decreases the levels of
eNOS in the rat penis. This decrease can be reversed by
administration of testosterone.28 It seems likely that the
observed eNOS increases in our study are due to increased
microvascular density and/or improved vascular endothe-
lial cell function.
nNOS is present in significant amounts in the skeletal
(and the related cardiac muscle), where it is associated
with the sarcolemmal membrane and is activated by
calcium released during muscular contraction.29,30 In both
experimental (mdx mice) and natural (Duchenne muscular
dystrophy) models of skeletal muscle nNOS deficiency,
functional skeletal muscle ischemia has been detected
during exercise.31,32 Furthermore, non-specific pharmaco-
logical inhibition of NOS by the L-arginine analogue, L-
nitroarginine methyl esther (L-NAME), also impairs the
modulation of sympathetic vasoconstriction in the micro-
vasculature of exercising human skeletal muscle, leading to
functional ischemia.33
Decreased iNOS might indicate a reduction in the skel-
etal muscle inflammation. An inflammatory environment is
thought to be a cause of muscle dysfunction in COPD.4
Acute exercise is known to increase muscle inflammation.Despite this, the group receiving both resistance training
and testosterone had a reduction in absolute iNOS levels.
This is of particular interest as it might provide another
rationale for testosterone supplementation during exercise
training.
There are several limitations to our study. As this was an
interventional study, a healthy control group was not
included. The differences in the levels of NOS isoforms
between healthy and COPD subjects have previously been
examined by Montes et al.16 The levels of NOS isoforms
detected in our study were roughly one-tenth of the values
reported in COPD patient in the aforementioned study. This
apparent discrepancy between studies is likely due to the
different assays and controls used. While the testosterone
aspect of the studywas performed in a double-blind placebo-
controlled fashion, the exercise portion did not include
a sham-exercise arm. Our studywas only ten-weeks long. Any
potential longer-term effects of the interventions would,
therefore, not be observed. By design, all of our subjects
weremen. As a result, the findings cannot be extrapolated to
the mixed-gender COPD population. Given the relatively
small sample size, the results could not be meaningfully
adjusted for differences in the mean levels of baseline vari-
ables among groups.
To best of our knowledge, the current study is the only
one to date that has examined the effects of interventions
(resistance training, testosterone supplementation) on the
expression of NOS isoforms in the skeletal muscle of COPD
patients. The observed increases in eNOS and nNOS would
be predicted to favorably alter oxygen supply to the exer-
cising muscle. The reduction in the iNOS level in the
combined resistance training/testosterone supplementa-
tion is of particular interest, as it could potentially reflect
an anti-inflammatory effect. We view our study as
hypothesis generating. Larger, longer-term clinical studies
in both genders will be required to establish any potential
therapeutic significance of these findings.
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